Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
There have been recent important changes to adjuvant regimens and costs of taxanes for the treatment of early breast cancer, requiring a re-evaluation of comparative cost effectiveness. In particular, weekly paclitaxel is now commonly used but has not been subjected to cost-effectiveness analysis.
Our aim was to estimate the cost effectiveness of adjuvant docetaxel and weekly paclitaxel versus each other, and compared with standard 3-weekly paclitaxel, in women aged ≥25 years diagnosed with regional breast cancer in New Zealand.
A macrosimulation Markov model was used, with a lifetime horizon and health system perspective. The model compared 3-weekly docetaxel and weekly paclitaxel versus standard 3-weekly paclitaxel (E1199 regimen) in the hospital setting. Data on overall survival and toxicities (febrile neutropenia and peripheral neuropathy) were derived from relevant published clinical trials. Epidemiological and cost data were derived from New Zealand datasets. Health outcomes were measured with health-adjusted life-years (HALYs), similar to quality-adjusted life-years (QALYs). Costs included intervention and health system costs in year 2011 values, with 3 % per annum discounting on costs and HALYs.
The mean HALY gain per patient compared with standard 3-weekly paclitaxel was 0.51 with weekly paclitaxel and 0.21 with docetaxel, while incremental costs were $NZ12,284 and $NZ4,021, respectively. The incremental cost-effectiveness ratio (ICER) of docetaxel versus 3-weekly paclitaxel was $NZ19,400 (purchasing power parity [PPP]-adjusted $US13,100) per HALY gained, and the ICER of weekly paclitaxel versus docetaxel was $NZ27,100 ($US18,300) per HALY gained. In terms of net monetary benefit, weekly paclitaxel was the optimal strategy for willingness-to-pay (WTP) thresholds >$NZ27,000 per HALY gained. However, the model was highly sensitive to uncertainty around survival differences, while toxicity-related morbidity had little impact. Thus, if it was assumed that weekly paclitaxel and docetaxel had the same efficacy, docetaxel would be favoured over weekly paclitaxel.
Both weekly paclitaxel and docetaxel are likely to be cost effective compared with standard 3-weekly paclitaxel. Weekly paclitaxel was the optimal choice for WTP thresholds greater than $NZ27,000 per HALY gained (PPP-adjusted $US18,000). However, uncertainty remains around relative survival benefits, and weekly paclitaxel becomes cost ineffective versus docetaxel if it is assumed that the two regimens have equal effectiveness. Reduced uncertainty about the relative survival benefits may improve decision making for funding.
- Cancer: new registrations and deaths 2010. Ministry of Health, Wellington
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: pp. 1687-1717 CrossRef
- Management of breast cancer in women: a national clinical guideline. Scottish Intercollegiate Guidelines Network, Edinburgh
- New Zealand Guidelines Group. Management of early breast cancer: evidence-based best practice guideline. Wellington; 2009.
- Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007; (4):CD004421. doi:10.1002/14651858.CD004421.pub2.
- Breast Cancer Disease Site Group. Adjuvant taxane therapy for women with early-stage, invasive breast cancer. Program in Evidence-based Care Evidence-Based Series No. 1–7 Version 2. Toronto (ON): Cancer Care Ontario; 2011.
- Recommendations for use of taxane-containing chemotherapy regimens for the treatment of early (operable) breast cancer: clinical practice guideline. Cancer Australia, Sydney (NSW)
- Early and locally advanced breast cancer: diagnosis and treatment. National Institute for Health and Care Excellence (NICE), London
- PHARMAC. Proposal to widen access to docetaxel: consultation letter. Wellington: PHARMAC; 2011.
- Wolowacz, SE, Cameron, DA, Tate, HC, Bagust, A (2008) Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol 26: pp. 925-933 CrossRef
- Au, HJ, Golmohammadi, K, Younis, T, Verma, S, Chia, S, Fassbender, K (2009) Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Res Treat 114: pp. 579-587 CrossRef
- Marino, P, Siani, C, Roche, H, Protiere, C, Fumoleau, P, Spielmann, M (2010) Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study. Ann Oncol 21: pp. 1448-1454 CrossRef
- Younis, T, Rayson, D, Sellon, M, Skedgel, C (2008) Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat 111: pp. 261-267 CrossRef
- Younis, T, Rayson, D, Skedgel, C (2011) The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. Curr Oncol 18: pp. e288-e296 CrossRef
- Martin-Jimenez, M, Rodriguez-Lescure, A, Ruiz-Borrego, M, Segui-Palmer, MA, Brosa-Riestra, M (2009) Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin Transl Oncol 11: pp. 41-47 CrossRef
- Ward, S, Simpson, E, Davis, S, Hind, D, Rees, A, Wilkinson, A (2007) Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 11: pp. 1-144
- Limwattananon, S, Limwattananon, C, Maoleekulpairoj, S, Soparatanapaisal, N (2006) Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer. J Med Assoc Thail 89: pp. 690-698
- Sparano, JA, Wang, M, Martino, S, Jones, V, Perez, EA, Saphner, T (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358: pp. 1663-1671 CrossRef
- PHARMAC. New Zealand pharmaceutical schedule, vol. 18, no. 1. PHARMAC; Wellington; 2011.
- PHARMAC. New Zealand pharmaceutical schedule: vol. 18 , no. 2. PHARMAC; Wellington; 2011.
- PHARMAC. New Zealand pharmaceutical schedule: section H for hospital pharmaceuticals. PHARMAC; Wellington; 2011.
- Laurentiis, M, Cancello, G, D’Agostino, D, Giuliano, M, Giordano, A, Montagna, E (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26: pp. 44-53 CrossRef
- Qin, Y-Y, Li, H, Guo, X-J, Ye, X-F, Wei, X, Zhou, Y-H (2011) Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One 6: pp. e26946 CrossRef
- Bria, E, Nistico, C, Cuppone, F, Carlini, P, Ciccarese, M, Milella, M (2006) Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 106: pp. 2337-2344 CrossRef
- Giménez Poderós T, Gaminde Inda I, Iruin Sanz A, Napal Lecumberri V. Taxanos en el tratamiento adyuvante del cáncer de mama con ganglios positivos: metanálisis [Taxanes in the adjuvant therapy of breastcancer with positive nodes: a meta-analysis]. Farm Hosp. 2005;29:75–85.
- Blakely T, Foster R, Wilson N, Bode3 Team. Burden of Disease Epidemiology, Equity and Cost-Effectiveness (BODE3) Study Protocol. Version 2.0. Wellington: Department of Public Health, University of Otago, Wellington; 2012.
- Salmond, C, Crampton, P, Atkinson, J (2007) NZDep2006 index of deprivation. Department of Public Health, University of Otago, Wellington
- Kuderer, NM, Dale, DC, Crawford, J, Cosler, LE, Lyman, GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: pp. 2258-2266 CrossRef
- Costilla R, Atkinson J, Blakely T. Incorporating ethnic and deprivation variation to cancer incidence estimates over 2006–2026 for the ABC-CBA model. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme—Technical Report No. 5. Wellington: Department of Public Health, University of Otago, Wellington; 2011.
- Blakely T, Costilla R, Soeberg M. Cancer excess mortality rates over 2006–2026 for ABC-CBA. Burden of Disease Epidemiology, Equity and Cost-Effectiveness programme, Technical Report No. 10. Wellington: Department of Public Health, University of Otago, Wellington; 2012.
- Kvizhinadze G, Blakely T. Projected New Zealand lifetables. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme (BODE3). Technical Report: No. 4. Wellington: Department of Public Health, University of Otago, Wellington; 2011.
- Roche, H, Fumoleau, P, Spielmann, M, Canon, JL, Delozier, T, Serin, D (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24: pp. 5664-5671 CrossRef
- Martin, M, Rodriguez-Lescure, A, Ruiz, A, Alba, E, Calvo, L, Ruiz-Borrego, M (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 100: pp. 805-814 CrossRef
- Salomon, JA, Vos, T, Hogan, DR, Gagnon, M, Naghavi, M, Mokdad, A (2012) Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380: pp. 2129-2143 CrossRef
- Eiermann, W, Pienkowski, T, Crown, J, Sadeghi, S, Martin, M, Chan, A (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29: pp. 3877-3884 CrossRef
- Ellis, P, Barrett-Lee, P, Johnson, L, Cameron, D, Wardley, A, O’Reilly, S (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373: pp. 1681-1692 CrossRef
- Citron, ML, Berry, DA, Cirrincione, C, Hudis, C, Winer, EP, Gradishar, WJ (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: pp. 1431-1439 CrossRef
- Loesch, D, Greco, FA, Senzer, NN, Burris, HA, Hainsworth, JD, Jones, S (2010) Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol 28: pp. 2958-2965 CrossRef
- Henderson, IC, Berry, DA, Demetri, GD, Cirrincione, CT, Goldstein, LJ, Martino, S (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: pp. 976-983 CrossRef
- Perez, EA, Suman, VJ, Davidson, NE, Gralow, JR, Kaufman, PA, Visscher, DW (2011) Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29: pp. 4491-4497 CrossRef
- Madarnas, Y, Dent, SF, Husain, SF, Robinson, A, Alkhayyat, S, Hopman, WM (2011) Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres. Curr Oncol 18: pp. 119-125 CrossRef
- Hershman, DL, Weimer, LH, Wang, A, Kranwinkel, G, Brafman, L, Fuentes, D (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125: pp. 767-774 CrossRef
- Pharmaco (NZ) Limited. Data sheet: paclitaxel ebewe injection concentrate. Auckland; 2011.
- Swain, SM, Arezzo, JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6: pp. 455-467
- Argyriou, AA, Koltzenburg, M, Polychronopoulos, P, Papapetropoulos, S, Kalofonos, HP (2008) Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 66: pp. 218-228 CrossRef
- Foster, R, Blakely, T, Wilson, N, O’Dea, D (2012) Protocol for direct costing of health sector interventions for economic modelling (including event pathways). Department of Public Health, University of Otago, Wellington
- Baal, PH, Feenstra, TL, Polder, JJ, Hoogenveen, RT, Brouwer, WB (2011) Economic evaluation and the postponement of health care costs. Health Econ 20: pp. 432-445 CrossRef
- Statistics New Zealand. Gross domestic product. 2013. http://www.stats.govt.nz/browse_for_stats/economic_indicators/GDP/GrossDomesticProduct_HOTPDec12qtr/Tables.aspx. Accessed 17 May 2013.
- World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE): cost-effectiveness thresholds. 2013. http://www.who.int/choice/costs/CER_thresholds/en/. Accessed 17 May 2013.
- Lyman, GH, Dale, DC, Crawford, J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21: pp. 4524-4531 CrossRef
- Bonadonna, G, Valagussa, P, Moliterni, A, Zambetti, M, Brambilla, C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332: pp. 901-906 CrossRef
- Wood, WC, Budman, DR, Korzun, AH, Cooper, MR, Younger, J, Hart, RD (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: pp. 1253-1259 CrossRef
- Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32. doi:10.1016/j.ejca.2010.10.013.
- Begg, SJ, Vos, T, Barker, B, Stanley, L, Lopez, AD (2008) Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust 188: pp. 36-40
- The price of cancer: the public price of registered cancer in New Zealand. University of Otago, Wellington
- Ministry of Health, District Health Boards New Zealand. Purchase Unit Data Dictionary (PU DD) 2011/2012; 2011.
- Ministry of Health. Guide to the National Travel Assistance (NTA) Policy 2005: August 2009. Wellington: Ministry of Health; 2009.
- The National Pricing Programme Casemix Cost Weights Project Group. New Zealand casemix framework for publicly funded hospitals (including WIESNZ11 methodology and casemix purchase unit allocation) for the 20011/12 financial year: specification for implementation on NMDS. Wellington: District Health Boards New Zealand, Ministry of Health; 2011.
- Ministry of Health. WIESNZ11 cost weights. Ministry of Health, Wellington. 2011. http://www.health.govt.nz/nz-health-statistics/data-references/weighted-inlier-equivalent-separations/wiesnz11-cost-weights. Accessed 7 March 2013.
- Dooley, MJ, Singh, S, Michael, M (2004) Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer 12: pp. 653-656
- Sacco, JJ, Botten, J, Macbeth, F, Bagust, A, Clark, P (2010) The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One 5: pp. e8933 CrossRef
- Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand
Volume 32, Issue 7 , pp 707-724
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Burden of Disease Epidemiology, Equity and Cost-Effectiveness (BODE3) Programme, University of Otago-Wellington, PO Box 7343, 23 Mein Street, Newtown, Wellington, New Zealand
- 2. Department of Oncology, Auckland City Hospital, Park Road, Grafton, Auckland, New Zealand